<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4693">
  <stage>Registered</stage>
  <submitdate>3/11/2014</submitdate>
  <approvaldate>3/11/2014</approvaldate>
  <nctid>NCT02288208</nctid>
  <trial_identification>
    <studytitle>Phase I Safety and Tolerability Study of Birinapant in Chronic Hepatitis B</studytitle>
    <scientifictitle>Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose, Safety, Tolerability and Pharmacokinetics Study of Birinapant in Subjects With Chronic Hepatitis B</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>TL32711-POC-0095-PTL</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis B</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Antiviral Therapy (tenofovir or entecavir)
Treatment: drugs - Birinapant
Treatment: drugs - Placebo (for birinapant)

Experimental: Antiviral Therapy &amp; Birinapant - Antiviral therapy (tenofovir 300 mg or entecavir 0.5 mg) taken once daily by mouth, and birinapant administered as a 30 minute IV infusion once weekly for four weeks.

Placebo Comparator: Antiviral Therapy &amp; Placebo - Antiviral therapy (tenofovir 300 mg or entecavir 0.5 mg) taken once daily by mouth, and placebo (for birinapant) administered as a 30 minute infusion once weekly for four weeks.


Treatment: drugs: Antiviral Therapy (tenofovir or entecavir)


Treatment: drugs: Birinapant


Treatment: drugs: Placebo (for birinapant)


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Number of participants with adverse events</outcome>
      <timepoint>From Screening through end of study, up to 13 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics of birinapant (in plasma): maximum concentration (Cmax), time of maximum concentration (Tmax), area under the curve (AUC) extrapolated to time infinity, AUC from dosing to last quantifiable concentration</outcome>
      <timepoint>Day -1 through Day 26</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics of birinapant (in plasma): terminal elimination half-life (t1/2), clearance (CL), terminal disposition rate constant,volume of distribution (Vdss)</outcome>
      <timepoint>Day -1 through Day 26</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacokinetics of oral antiviral medication (tenofovir or entecavir): Cmax, Tmax, AUC from dosing to last quantifiable concentration, t1/2, CL, terminal disposition rate constant, Vdss</outcome>
      <timepoint>Day -1, Day 1 and Day 22</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hepatitis B markers (Determine levels of HBsAg, HBeAg, HBV DNA, and HBsAb) - Determine levels of HBsAg, HBeAg, HBV DNA, and HBsAb</outcome>
      <timepoint>Screening through Day 29</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pharmacodynamic effect of birinapant on cIAP1 and cIAP2 levels in peripheral blood mononuclear cells (PBMC) and levels of cluster of differentiation 4 and 8 (CD4+, CD+8) lymphocytes</outcome>
      <timepoint>Screening through Day 29</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Documented history of chronic Hepatitis B infection currently being treated with
             tenofovir or entecavir for at least 3 months

          -  Measurable titer of HBsAg

          -  HBV DNA level &lt; 2 log copies/mL or 10² copies/mL

          -  No more than Child-Pugh score of 5 plus a valid FibroScan® of at least 10 readings
             with a median score of &lt;7 and interquartile range of &lt; 30%

          -  Adequate liver function, aspartate AST and ALT =2 x ULN

          -  Adequate renal function as evidenced by creatinine =2 mg/dL</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Participation in any interventional study within 4 weeks prior to Screening

          -  Known HIV infection, Hepatitis C, or other significant hepatic disorder including
             cirrhosis (Child-Pugh Class B or C)

          -  Serious illness or autoimmune disease or other known liver disease

          -  Uncontrolled hypertension

          -  Impaired cardiac function, uncontrolled cardiac arrhythmias despite medications, or
             clinically significant cardiac disease

          -  Currently breast feeding, pregnant or planning on becoming pregnant

          -  Known allergy or hypersensitivity to any of the formulation components of birinapant
             or placebo, including citric acid

          -  History of cranial nerve palsy

          -  Current treatment with anti-TNF therapies or has received treatment with anti-TNF
             therapies within the last 6 months

          -  Use of non-steroidal anti-inflammatory drugs</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>7</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,VIC,WA</recruitmentstate>
    <hospital>CMAX / Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Nucleus Network Limited / AMREP Precinct - Melbourne</hospital>
    <hospital>Linear Clinical Research Ltd - Nedlands</hospital>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3004 - Melbourne</postcode>
    <postcode>6009 - Nedlands</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>TetraLogic Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study evaluates the addition of birinapant in subjects with chronic Hepatitis B who are
      currently receiving anti-viral therapy with either tenofovir or entecavir. Patients will
      receive either birinapant or placebo in addition to their anti-viral therapy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02288208</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>